AboutContact us
dotsbydots
SEARCHCONTACT US

Buzz

Most popular

Daily
Weekly
1
Unit 8200 veterans raise $22 million Series A for real-time impersonation defense
2
Cybereason founders' 7AI raises record $130 million Series A in breakneck rise
3
Check Point raises $1.75 billion, potentially eyeing AI expansion
4
Nice puts Actimize up for sale at a $1.5-2 billion price tag
5
Hapag-Lloyd eyes ZIM acquisition, workers push back
More news

Generics

6 stories about Generics
קור שולץ מנכ"ל טבע 9.11.19

Teva Is Pulling an Ace From its Sleeve in its Attempt to Reinvent Itself

11.11.19|Uri Tal-Tene
With one anti-cancer biosimilar launching this week and another expected to hit the market soon, Teva could be creating a new growth engine worth hundreds of millions of dollars a year
ה מטה הנוכחי של טבע ב ארה"ב

Mylan Cuts Price of Generic Copaxone Offering by 60%

11.07.18|Lilach Baumer
Mylan has achieved a 15%-20% market share in the U.S. since launching its generic version in late 2017 with a monthly price tag of $5,000, compared to Teva's $5,800
קאר שולץ מנכל טבע

Teva to Relocate U.S. Headquarters to New Jersey

08.07.18|Lilach Baumer
In December, the Israeli drugmaker announced a far-reaching cost cutting plan to deal with its multi-billion debt
קאר שולץ מנכל טבע

Goldman Sachs Sees 16% Upside in Teva Stock

26.06.18|Dror Reich
Following a meeting with Teva’s management, the bank's analysts reiterated their "buy" recommendation with a higher target price
יו"ר ועד עובדי טבע כפר סבא אלירן קוזליק

In Protest of New Bonus Plan, Teva Sued by Israeli Employees

15.03.18|Dror Reich
After announcing the cancellation of its annual bonuses for 2017 due to debt, the Israel-based drugmaker rolled out a performance-based bonus scheme for 2018 in February
מנכ"ל טבע גנריקה סיגורדור סיגי אולפסון

Drugmaker Hikma Appoints Former Teva Executive as CEO

20.02.18|Asaf Shalev
The appointment of Sigurdur Olafsson comes as Hikma has been struggling to bolster the performance of its generic drugs unit